Company intelligence / Profile preview
YD Global Life Science
- Ownership
- Private
- Employees
- ~49
- Development stage
- Other
Overview
YD Global Life Science is a Korean biopharmaceutical company focused on new drug development using proprietary AI technology, with an active pipeline in preclinical and discovery stages targeting ophthalmology, oncology, neurodegeneration, and rare diseases. The company has commercialized genetic diagnostic products locally.[2][5] No published clinical trial results or late-stage data are available.
- Therapeutic areas
- OphthalmologyOncologyPulmonologyNeurology
- Modalities
- Small molecule drugsBiological products (biologics)Chemical drugsGene therapy[2][7]
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on YD Global Life Science.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YD Global Life Science.